23RD IN

FECTIO

N AND

SEPS

IS SY

MPOSIU

M ANTIBIOTIC THERAPY COURSE09-10 MARCH | HOSPITAL LUSÍADAS | PORTO

CONGRESS COURSES:

07 - 09

MAR

CH 20

18 | S

HERATON PORTOANTIBIOTIC STEWARDSHIP- LESSONS LEARNED- IMPLEMENTING SUCCESSFUL PROGRAMS- ENGAGING KEY STAKEHOLDERSCHALLENGING INFECTIONS- SEVERE INFECTIONS BY XDR BUGS- IMMUNOCOMPROMISED HOSTS- THE ROLE OF THE NEWER BETA-LACTAMSSEPSIS: THE WAY FORWARD- IMPACT OF THE REVISED DEFINITIONS- BIG DATA ANALYSIS- NOVEL THERAPEUTIC TARGETS

MAIN TOPICS:

1 2

09h00-10h30 Antimicrobial Stewardship – 2018Chairmen: António Sarmento | Dulce Pascoalinho

- Implementing an effective AMS program - Strategies to improve the contribution of the micro lab- Engaging key stakeholders

Carlos Alves

Vittorio Sambri

Massimo Sartelli

10h30-11h00 Surviving in an endemic situation - George DimopoulosChairman: Álvaro Ayres Pereira

11h00-11h20 Coffee-Break11h20-11h40 Opening Session11h40-13h10 Emerging Threats

Chairmen: Manuela Ribeiro | TBA

- Candida Auris- Invasive aspergillosis in critically ill patients - Are we neglecting MRSA?

José Manuel Pereira

Stijn Blot

José Melo Cristino

13h10-13h40 Accelerate Satellite Symposium: Clinical value of faster antimicrobial susceptibility testing - Tiziana Di Martino

13h40-15h00 Lunch15h00-15h30 Assessment of MDR risk - focus on ESBL - Nuno Pereira

Chairman: J. Saraiva da Cunha

15h30-17h00 The way forwardChairmen: José Artur Paiva | José Neves

- The National Program of Infection Control and Antimicrobial Resistance: Opportunities and Challenges - Optimizing the yield of blood cultures- Money makes the world go around: economic impact of AMS

Isabel Neves

Vittorio Sambri

Carlos Palos

17h00 Poster Presentation17h00-17h30 Coffee-break17h30-18h00 A research agenda on infection in the ICU - Stijn Blot

Chairman: Paulo Mergulhão

09h00-10h30 Infections in transplant recipientsChairmen: Filomena Faria | Júlio Nóbrega

- An overview of infections in transplant recipients- Lung transplant- HSCT

Gerardo Oliveira

Carla Damas

Ricardo Pinto

10h30-11h00 Severe PsA infection in 2018 - David P. NicolauChairman: Paulo Mergulhão

11h00 Poster Presentation11h00-11h30 Coffee-break11h30-13h00 Carbapenem-resistant enterobactereacea

Chairmen: João João Mendes/ TBA

- The conundrum of telling colonisation from infection- Treatment of bacteraemia- Once a carrier, always a carrier?

Lurdes Santos

George Dimopoulos

Cláudia Nazareth

13h00-13h30 Astellas Satellite Symposium: Invasive Candidiasis- António Messias

13h30-15h00 Lunch15h00-16h30 TDM

Chairmen: João Pedro Baptista | Rui Veiga

- Pk/Pd targeted therapy: what are we missing?- What do we really know about MIC targets?- Aminoglicosides - what has changed?

David P. Nicolau

Jan de Waele

João Gonçalves Pereira

16h30-17h00 Source control in abdominal sepsis: what do we really know? - Massimo SartelliChairman: Irene Aragão

17h00 Poster Presentation17h00-17h30 Coffee-break17h30-18h30 The pipeline

Chairmen: João Gonçalves Pereira | Edgar Botelho Moniz

- Advantages and pitfalls of the new β-lactams- Novel antifungal agents- Innovative views to combat infection

Márcio Borges-Sá

Jan de Waele

George Dimopoulos

3 4

09h00-09h30 Assessing prognosis in AKI - Sérgio GaiãoChairman: TBA

09h30-10h00 Optimal fluid management in sepsis - Miguel TavaresChairman: TBA

10h00 Poster Presentation10h00-10h30 Coffee-Break10h30-12h00 Sepsis

Chairmen: Paula Coutinho | Rui Moreno

- New Sepsis definitions: advantages and pitfalls- Can big data change the way we practice medicine?- SSC 2016 recommendations and the National Guidelines

Paulo Mergulhão

Márcio Borges-Sá

Júlio Nóbrega

12h00-12h30 Sepsis in 2018: Lessons learned and future perspectives - José Artur PaivaChairman: Jorge Pimentel

12h30-13h00 Closing conference: The Infection and Sepsis Group 2018-9

5 6

7 8

C/T S (%) C/T R (%)

Enterobacterales (77) 39 61

E. coli ESBL + (13) 77 23

E. coli ESBL – (4) 100 -

K. pneumonia ESBL + (28) 28,6 71,4

K. pneumonia ESBL - (14) 21,4 78,6

Other Enterobacterales (18) 27,8 72,2

P. aeruginosa (12) 83,3 16,7

9 10

Antimicrobiano Resistência (%)

Imipenem 90,6

Meropenem 90,3

Gentamicina 56,1

Amicanina 47,2

Ceftazidima 38,9

Piperacilina-tazobactam 90,9

Ciprofloxacina 85,9

Colistina 0

Ceftolozano-tazobactam 14,6

11 12

13 14

15 16

17 18

19 20

21

MAJOR SPONSORS

B|BRAUN

SPONSORS

Grupo de

Infecção e Sepsis